Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema vs Semaglutide in Obesity With or Without Type 2 Diabetes
NCT07564414Phase 3Recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Primary completion
- Feb 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 19
01
Overview
A Phase 3 trial of CagriSema in obesity, sponsored by Novo Nordisk. Started May 2026; status: recruiting.
02
Drugs
CagriSema
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07564414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07564414.